Benefits of subretinal implants revealed

Article

Findings from Retina Implant AG's first human clinical trial of subretinal electronic implants have revealed that useful vision can be restored and a significant cost-benefit to the patient's quality of life gained.

Findings from Retina Implant AG's first human clinical trial of subretinal electronic implants have revealed that useful vision can be restored and a significant cost-benefit to the patient's quality of life gained. These outcomes were discussed in two oral presentations at the recent The Eye and The Chip 2010 meeting in Detroit, USA.

The first presentation by Dr Eberhart Zrenner, Institute for Ophthalmic Research at the University of Tübingen, Germany, demonstrated the clinical trial results of the subretinal electronic implants in patients with retinitis pigmentosa (RP). It began in November 2005 when 11 patients received 1500 pixel microchips implanted below the retina. Dr Zrenner concluded that using this level of microchip implantation that can move freely in the eye restores useful vision as well as the ability to read letters and form words.

“The data presented represents an important milestone in the fight to restore useful vision to individuals who are blind due to retinitis pigmentosa. It speaks to the patient's ability to easily begin benefiting from the subretinal implant even with little to no training,” reported Dr Zrenner. It was also stated during the presentation that a second clinical trial has already begun at several European sites where the patients will receive a permanent implant.

Dr Walter-G. Wrobel, CEO of Retina Implant AG, discussed further data from the first clinical trial on the cost-benefit associated with the implantation during the second oral presentation. It was reported that there was a significant cost-benefit associated with the retinal implant for the patient’s quality of life. “The primary goal of our first clinical trial was to provide useful vision to patients, but this study shows that such devices could be a cost-effective treatment for people blinded by retinal degeneration,” confirmed Dr Wrobel.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.